X
NOW AVAILABLE IN THE U.S.
Visit MIPLYFFA.com

Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers

/in , /by

Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate

/in , /by

Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD

/in , /by

Effect of Food and Alternative Dosing Methods on the Pharmacokinetics of KP415, an Investigational ADHD Product Containing the Prodrug, Serdexmethylphenidate (SDX)

/in , /by

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

/in , /by

Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

/in , /by

Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate

/in , /by

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

/in , /by

© 2025 Zevra Therapeutics. All rights reserved. | Privacy Policy | Terms of Use